登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Safety of Robotic Surgery for GISTs at Special Anatomic Sites
ClinicalTrials.gov 上登记的一项胃肠道间质瘤开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07405125,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Cardiac insufficiency classified as NYHA Class III-IV, or left ventricular ejection fraction (LVEF) <50% on cardiac ultrasound.
排除标准第 9 条
Myocardial infarction within 6 months prior to surgery, or poorly controlled arrhythmia (including QTc interval ≥450 ms for males or ≥470 ms for females, calculated using Fridericia's formula).
排除标准第 8 条
Any active infection requiring systemic anti-infective therapy within 14 days prior to surgery; except for prophylactic antibiotic therapy (e.g., for urinary tract infection or chronic obstructive pulmonary disease).
排除标准第 15 条
Preoperative ECOG Performance Status score of 0 or 1.
入选标准第 8 条
Human Immunodeficiency Virus (HIV) infection.
排除标准第 12 条
Pregnant or lactating female patients.
排除标准第 19 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07405125,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Aged 18 to 75 years, regardless of sex. Diagnosis of GIST located at a special anatomic site confirmed preoperatively by endoscopy/endoscopic ultrasound, CT, or MRI. Preoperative imaging suggests a tumor diameter between 2 cm and 5 cm. No prior neoadjuvant therapy (e.g., imatinib) administered. Expected survival period ≥ 6 months. Preoperative assessment indicates feasibility for robotic surgery. Preoperative examinations show no evidence of distant metastasis or direct invasion into adjacent organs. Preoperative ECOG Performance Status score of 0 or 1. Preoperative ASA Physical Status classification of I to III. The subject has read and fully understood the patient information sheet and provided written informed consent.排除标准:Exclusion Criteria:
History of previous upper abdominal surgery (except laparoscopic cholecystectomy). History of previous gastrectomy, endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD). Previous administration of neoadjuvant therapy (e.g., imatinib). Presence of other active malignancies within the past 5 years or concurrently. (Note: Patients with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervical carcinoma in situ, breast carcinoma in situ, Stage I lung cancer, or Stage I colorectal cancer, may be enrolled.) Requirement for concurrent surgery for other diseases. Emergency surgery performed due to tumor-related complications (bleeding, obstruction, or perforation). Arterial/venous thrombotic events within 6 months prior to screening, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis (excluding thrombosis related to prior chemotherapy venous catheters deemed resolved by the investigator), and pulmonary embolism. Myocardial infarction within 6 months prior to surgery, or poorly controlled arrhythmia (including QTc interval ≥450 ms for males or ≥470 ms for females, calculated using Fridericia's formula). Cardiac insufficiency classified as NYHA Class III-IV, or left ventricular ejection fraction (LVEF) <50% on cardiac ultrasound. Ventilatory dysfunction: FEV1 <50% of predicted value. Clinically symptomatic pleural or abdominal effusion requiring clinical intervention. Human Immunodeficiency Virus (HIV) infection. Active pulmonary tuberculosis. History or presence of interstitial lung disease, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired pulmonary function that may interfere with the detection or management of suspected drug-related pulmonary toxicity. Any active infection requiring systemic anti-infective therapy within 14 days prior to surgery; except for prophylactic antibiotic therapy (e.g., for urinary tract infection or chronic obstructive pulmonary disease). Concurrent participation in another clinical trial involving surgical treatment. History of alcohol abuse, drug abuse, or substance abuse. (Note: Patients who have ceased alcohol consumption may be enrolled.) Patients deemed likely to be non-compliant with medical advice or medication regimens, or with incomplete data that may affect efficacy or safety assessment. Pregnant or lactating female patients. Any condition that may increase the risk associated with study participation, or other severe, acute, or chronic diseases, or any other situation that, in the investigator's judgment, makes the patient unsuitable for clinical study participation.
引自 ClinicalTrials.gov, NCT07405125, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07405125,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。